Prion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases

Valerija Kovač and Vladka Ćurin Šerbec
Department for the Production of Diagnostic Reagents and Research, Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia.

ABSTRACT: Prion protein (PrP) is a biomolecule that is involved in neuronal signaling, myelination, and the development of neurodegenerative diseases. In the cell, PrP is shed by the ADAM10 protease. This process generates PrP molecules that lack glycophosphatidylinositol anchor, and these molecules incorporate into toxic aggregates and neutralize toxic oligomers. Due to this dual role, these molecules are important biomarkers for neurodegenerative diseases. In this review, we present shed PrP as a potential biomarker, with a focus on PrP226*, which may be the main biomarker for predicting neurodegenerative diseases in humans.

KEYWORDS: Prion disease, Alzheimer disease, neurodegenerative disease, shed PrP, PrP226*, ADAM10 protease

Introduction
Prion protein (PrP) is a naturally occurring glycoprotein. Prion protein binds to the cell membrane via a glycophosphatidylinositol (GPI) anchor and is abundantly present on the cell surfaces of neurons. PrP has many proposed functions, including the maintenance of myelination homeostasis, mitochondrial function, and intercellular signaling. For unknown reasons, the α-helix-rich 3-dimensional structure of the cellular form of PrP (PrPC) can transform into a β-sheet-rich molecule, which is the pathological form of PrP (PrPSc). PrPSc is unable to perform the same functions as PrPC and is prone to autocatalytic conversion and aggregation into insoluble aggregates. The accumulation of PrPSc aggregates over time results in disease.

Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, are rare fatal neurodegenerative disorders that occur in humans and animals. Prion diseases can be divided into 3 groups—sporadic, genetic, and iatrogenic. Sporadic diseases are the most common type, and their origins are unknown. Genetic prion diseases are the second most common type and are characterized by mutations in the PrP-encoding gene, PRNP. Iatrogenic prion diseases develop due to the consumption of PrPSc-infected tissue, after transplantation, after surgical interventions, and due to the use of infected growth hormone of human origin. All 3 forms have a different clinical picture but show similar symptoms of disease, such as dementia, the loss of brain function, and spongiform deformation of the brain. Prion diseases also have important clinical and neuropathological features that are similar to those of Alzheimer disease. Although prion disease occurs due to accumulation of toxic PrPSc aggregates in the brain, the mechanism that underlies the conversion of PrPC to PrPSc and the development of prion disease remains unknown.

PrPSc is linked to the cell membrane via a GPI anchor. Similar to other GPI-anchored proteins, PrPSc enters the endocytic recycling pathway. As the protein revolves between the cell surface and the endosome, the protein encounters both neutral and acidic pH. Many studies have shown that these environmental changes may cause the misfolding of PrP, leading to its transformation into the pathological form and to its accumulation.

During normal metabolism, PrPSc can undergo 5 posttranslational cleavages. Cleavages α and β occur within the highly conserved hydrophobic region of PrP in the endosomes and result in the release of a 10-kDa N-terminal fragment into the extracellular matrix. Cleavage γ presumably occurs during the transport of PrP through the secretary pathway before glycosylation. The cleavage near the GPI anchor produces a 6- to 7-kDa unglycosylated C-terminal fragment. Prion protein is also the target of shedding. Phospholipase C cleaves PrP within the GPI anchor, which leads to the release of the whole protein into the extracellular medium. Shed PrP is also produced by cleavage of the PrPSc polypeptide chain at the C-terminus by ADAM10 protease.

In hamsters, approximately 15% of PrPSc molecules, isolated from the prion-infected hamster brain, terminate at Gly228. In addition, in a recombinant hamster PrP model, ADAM10 protease cleaves PrP between amino acid residues Gly228 and Arg229. The cleavage site of ADAM10 protease in human PrPSc is not unambiguously defined. A cleavage site profile of ADAM10 was recently explored using peptide libraries and cleavage liquid chromatography-mass spectrometry analysis. The authors have shown that no unique sequence exists that induces cleavage. Therefore, ADAM10 protease can produce more than one variant of shed PrP. In the proximity of
the cleavage site, the sequence and 3-dimensional structure of human PrP differ from those of hamster PrP. Because the protein sequences are not identical, we can expect a different cleavage pattern for the ADAM10 protease. Consequently, we hypothesize that the proteolytic site in the human sequence is not located between amino acid residues 228 and 229 but is instead shifted toward the N-terminus, namely, between Tyr226 and Gln227 (Figure 1).

In addition to the brain, PrP without the GPI anchor is also found in the urine, cerebrospinal fluid, and blood of patients with different prion diseases and in controls. Most analyses concerning PrP have focused on finding PrPSc and determining infectivity; however, studies on PrPC and its variants in bodily fluids are few. Reports of PrP variants that lack the GPI anchor show that these molecules are involved in neurodegenerative diseases, where the molecules have different roles. These variants may thus be a useful tool for determining the mechanism of neurodegenerative diseases as well as for their diagnosis and therapy.

**PrPs That Lack the GPI Anchor**

**Anchorless PrP**

Analysis of aggregates in patients with sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome has shown that apart from PrPSc, aggregates are built from anchorless PrP and other variants of PrP without the GPI anchor. Initially, the conversion from PrPC to PrPSc was thought to occur only when PrPC was bound to the cell membrane by the GPI anchor, but a study by Chesebro and coworkers showed the opposite. Experiments on transgenic mice expressing only anchorless PrP showed that infection with PrPSc encouraged the accumulation of PrP in various tissues, such as the heart, kidney, and body fat. This accumulation led to the development of prion disease without clinical signs. Later, experiments on these mice confirmed that anchorless PrP could cause prion disease, even though the protein was not covalently bound to the cell surface. Anchorless PrP aggregates were found to spread and seed through the interstitial fluid and thus enable the development of cerebral amyloid angiopathy (CAA) in the brain. In addition, the recent study on transgenic mice expressing anchorless PrP showed that PrP without GPI anchor could propagate the infectivity of prion diseases within the same and among different species.

**PrP shed by ADAM10**

ADAM proteases cleave transmembrane proteins and affect cell interactions with their surroundings, cell migration, and cell signaling. Several research groups have shown that ADAM10 protease cleaves PrPC from the cell membrane, producing shed PrP. The effect of the protease was shown in 2 systems: PrPC-expressing human embryonic kidney (HEK) cells that were transfected with complementary DNA encoding for ADAM10 and neuron-specific ADAM10 knockout mice. The experiments in HEK cells showed an increase in the amount of soluble PrPC in the cell supernatant, whereas the experiments in the knockout mice showed an increase in the amount of membrane-linked PrPC and an increase in PrPSc formation, compared with the wild-type mice. Shedding is presumed to have an antagonistic role in the development of prion diseases. The primary product of shedding, shed PrP, is a molecule that freely floats in bodily fluids, binds PrPSc aggregates, and prevents their replication. However, when PrPSc aggregates bind to PrPC, PrPC is refolded into PrPSc and released from the cell membrane by ADAM10, generating new sources of infection. Prion protein is also involved in Alzheimer disease. Similar to PrPSc in prion diseases, toxic amyloid-β peptide oligomers (AβOs) bind to the N-terminus of GPI-anchored PrPC. When the expression of membrane-bound PrPC increases at the neuronal surface, the level of toxic AβO binding to membrane-bound PrPC also increases, causing cell damage. However, in the extracellular space, shed PrP binds to AβO and neutralizes it. ADAM10 protease can shed both PrPC and PrPSc, and therefore, the regulation of this mechanism may affect the development and occurrence of Alzheimer disease and prion diseases.
Truncated PrP due to nonsense mutations

Nonsense mutations in the PRNP gene are another source of PrPs that lack GPI anchor. Due to nonsense mutations, a codon that encodes for a specific amino acid changes into a stop codon, which leads to premature termination of the protein. The product is a truncated PrP that lacks the GPI anchor at the time of synthesis. Several cases of prion diseases that were caused by the expression and accumulation of truncated PrP have been described. The nonsense mutations that caused the disease were Y145X, 48 Q160X, 49,50 Y163X, 51,52 V203X, 53 Y226X, 50 and Q227X. 30 In the cases of Y145X, Y163X, and Y226X, the patients developed PrP-CAA. The PrP-CAA is characterized by amyloid deposits of PrP in cerebral vessels and by Alzheimer disease–like neurofibrillary tangles in the brain, predominantly in the hippocampus. 54 The distribution of PrPSc aggregates is similar to the distribution of PrP in transgenic mice expressing only anchorless PrP. The deletion of 2 base pairs in codon 178 causes a change in the protein sequence from codon 178 onward and results in a stop codon at codon 203. 50 This truncated PrP is deposited in almost all examined organs, namely, peripheral nerves, smooth muscles, and blood vessels in non-central nervous system tissues. The Q160X mutation leads to an illness that is similar to Alzheimer disease, whereas patients with the Q227X mutation develop a disease that is similar to the GSS syndrome. Interestingly, the insertion of stop mutations in the codon that codes for tyrosine results in PrP-C, whereas a premature stop in the codon sequence that codes for glutamine results in a different pathology. This difference may be due to the amino acid that terminates the variant’s protein sequence.

V5B2 and PrP226*

The methods used to determine the presence of PrPc and PrPSc in biological samples are based on antigen–antibody interactions. To find an antibody that discriminates between Creutzfeldt-Jakob disease (CJD) and non–CJD samples, we prepared monoclonal antibodies against PrP. BALB/c mice were immunized with a KLH-bound peptide fragment of the human PrP sequence (amino acid residues between 214 and 226). Using hybridoma technology, we prepared a panel of monoclonal antibodies against PrP, one of which was V5B2. 55 V5B2 differed from the other anti-PrP monoclonal antibodies because V5B2 recognized only a specific form of PrP. We determined and confirmed the epitope of monoclonal antibody V5B2 using an alanine scan and phage display approach examining the C-terminal region between amino acid residues 214 and 228. 56 We found that monoclonal antibody V5B2 recognized the anchorless truncated form of PrP that ended with amino acid residue Tyr226, and we named the variant PrP226*.

Using monoclonal antibody V5B2, we identified PrP226* in pathological samples and found that PrP226* was a remarkable biomarker for diagnosing prion diseases. Our immunohistochemistry, dot blot, and Western blot analyses of samples from a group of patients with sCJD showed that monoclonal antibody V5B2 specifically discriminated between the CJD and non–CJD brain. 29,55 We postulated that PrP226* incorporated into PrPSc aggregates in such a manner that the C-terminus was exposed on the aggregate surface or was hidden inside the molecule. The C-terminus of PrP226* represents the epitope of V5B2. To undoubtedly determine the presence of PrP226* in the PrPSc aggregates using this monoclonal antibody, we denatured the sample before the analysis to release all V5B2 epitopes from the aggregates. 27,29 Our monoclonal antibody also enables a sensitive determination of PrP226* in the brains of TSE patients using dissociation-enhanced lanthanide fluorescence immunoassay 30 and enzyme-linked immunosorbent assay. 27 In addition to PrP-infected samples, we have shown that PrP226* is also present in the healthy brain, albeit in small amounts. 27,29 We are not the only research group to describe this PrP form. As indicated above, PrP226* was concurrently described by Jansen and coworkers. 30 The authors characterized a patient who carried a stop mutation at position Q227X and developed a disease similar to GSS syndrome.

PrP226* causes disease, and minor quantities of PrP226* are also present in the brains of healthy individuals. We suspect that this protein is produced through natural processes, such as shedding or nonsense mutations, and that under yet undefined conditions, PrP226* can act as a propagator of disease. Based on the nature of PrP226*, namely, its presence in human brain and body fluids (unpublished data), lack of GPI anchor, slight truncation at the C-terminus, and neutralization and pathological capacity, we speculate that PrP226* is produced by shedding. To determine whether PrP226* could be the result of cleavage by ADAM10, we analyzed the amount of PrP226* in the human brain. The PrP226* amount, which we determined in the brains of subjects with sCJD, is approximately 12% (unpublished data), which is similar to the amount of truncated PrP determined in the hamster. 20 Based on the properties of PrP226* in vivo, we have indirect evidence supporting PrP226* in humans as one of the products, if not the only product, of ADAM10 shedding (Figure 1).

Structure and conversion properties of PrP226*

Recently, we examined the structural and biochemical properties of PrP226* and resolved the high-resolution nuclear magnetic resonance structure of the protein under acidic conditions (PDB ID 5L6R). 57 The structure of the protein reveals a disordered region between residues 90 and 125 and a structured region between residues 126 and 226. The structured region consists of 2 β-sheets and, compared with wild-type PrP, has 4 α-helices instead of 3 α-helices. As the C-terminus is truncated, new interactions within the structure are needed to stabilize the protein. To do that, the amino acid residues at the C-terminus are driven into the proximity of the amino acid residues of the flexible loop. This causes a minor change in the structure, electrostatic potential and solvent accessibility of the
C-terminus, and flexible loop compared with the wild-type molecule. Similar observations have also been made in structural studies of various pathogenic mutants that cause TSE, namely, Q212P\textsuperscript{58} and V210I.\textsuperscript{59}

We also determined the thermodynamic properties and \textit{in vitro} conversion propensity of PrP\textsubscript{226}\textsuperscript{*} at acidic and physiological pH.\textsuperscript{60} We found that in both conditions, PrP\textsubscript{226}\textsuperscript{*} is more thermodynamically destabilized than the wild-type protein. Furthermore, the fibrillation propensity of PrP\textsubscript{226}\textsuperscript{*} was similar to that of the wild-type PrP in physiological conditions, and the fibril formation onset time at acidic pH for PrP\textsubscript{226}\textsuperscript{*} increased compared with that of the wild-type protein. Alongside PrP\textsubscript{226}\textsuperscript{*}, we analyzed variants that were similar to PrP\textsubscript{226}\textsuperscript{*}. One variant, PrP\textsubscript{225}\textsuperscript{*}, had similar thermodynamic properties to those of PrP\textsubscript{226}\textsuperscript{*}, but the fibrillation propensity was shorter than that of PrP\textsubscript{226}\textsuperscript{*}. A similar trend to that observed \textit{in vitro} was observed \textit{in vivo}. Jansen and coworkers\textsuperscript{60} reported that the time of onset of prion disease, which resulted from expression of only PrP\textsubscript{225}\textsuperscript{*}, was 27 months, whereas the time of onset of prion disease, which resulted from PrP\textsubscript{226}\textsuperscript{*} expression alone, was longer, namely, 72 months. In addition to the time of disease onset, the expression of the 2 PrP variants differentially affected the development of prion diseases, resulting in different pathologies. In conclusion, the \textit{in vivo} and \textit{in vitro} data suggest that a change in the protein length, even by 1 amino acid residue, can have a profound effect on \textit{in vitro} and \textit{in vivo} conversion.

Conclusions

Neurotoxicity occurs at the cell surface, where toxic oligomers bind to membrane-anchored PrPC. Binding of PrP\textsubscript{Sc} oligomers to membrane-bound PrPC transforms the native molecule into PrP\textsubscript{Sc}, which can be shed from the cell surface by ADAM10 protease. In other words, these molecules can be potent biomarkers for the diagnosis of neurodegenerative diseases, particularly PrP\textsubscript{226}\textsuperscript{*}, in the mechanism behind neurodegenerative diseases. ADAM10 protease does not have a unique proteolytic site for prion protein processing and thus, these molecules can be potent biomarkers for the development of therapy.

Author Contributions

VK and VČŠ contributed to the writing of the manuscript, confirmed the manuscript results and conclusions, jointly developed the structure and arguments of the paper, made critical revisions and approved the final version, and have reviewed and approved the final manuscript.

REFERENCES

1. Prusiner SB. Prions. \textit{Proc Natl Acad Sci U S A.} 1998;95:13363–13383.
2. Aguzzi A, Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. \textit{Nat Rev Microbiol.} 2006;4:765–775.
3. Herms J, Tings T, Gall S, et al. Evidence of presynaptic location and function of the prion protein. \textit{J Neurosci.} 1999;19:8866–8875.
4. Kuffer A, Lakkaraju AK, Mogha A, et al. The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. \textit{Nature.} 2016;536:464–468.
5. Faris R, Moore RA, Ward A, et al. Cellular prion protein is present in mitochondria of healthy mice. \textit{Sci Rep.} 2017;7:41556.
6. Harris DA. Cellular biology of prion diseases. \textit{Clin Microbiol Rev.} 1999;12:429–444.
7. Slapišk U, Salzano G, Amin L, et al. The N terminus of the prion protein mediates functional interactions with the neuronal cell adhesion molecule (NCAM) fibronectin domain. \textit{J Biol Chem.} 2016;291:21857–21868.
8. Wulf M-A, Senatore A, Aguzzi A. The biological function of the cellular prion protein: an update. \textit{BMC Biol.} 2017;15:34.
9. Harris DA. Trafficking, turnover and membrane topology of PrP. \textit{Br Med Bull.} 2003;66:71–85.
10. Mayor S, Sabharanjak S, Maxfield FR. Cholesterol-dependent retention of GPI-anchored proteins in endosomes. \textit{EMBO J.} 1998;17:4626–4638.
11. Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. \textit{Nat Rev Mol Cell Biol.} 2010;11:50–61.
12. Godsave SF, Wille H, Kujala P, et al. Cryo-immunogold electron microscopy for the assessment of conformational changes in the prion protein. \textit{Proc Natl Acad Sci U S A.} 1998;95:13363–13383.
13. Crouch PJ, Klug GM, Hooper NM, Collins SJ. Prion protein mutant. \textit{Biochemistry.} 2007;46:3045–3054.
14. Biljan I, Ik G, Guschin G, Plavec J, Legname G. Structural rearrangements at physiological pH: nuclear magnetic resonance insights from the V210I human prion protein mutant. \textit{Biochemistry.} 2012;51:7465–7474.
15. DeMarco ML, Daggett V. Molecular mechanism for low pH triggered misfolding of the human prion protein. \textit{Biochemistry.} 2007;46:3045–3054.
16. Calzolai L, Zahn R. Influence of pH on NMR structure and stability of the human prion protein globular domain. \textit{J Biol Chem.} 2003;278:35592–35596.
17. Lewis V, Johanssen VA, Crouch PJ, Klug GM, Hooper NM, Collins SJ. Prion protein "gamma-cleavage": characterizing a novel endoproteolytic processing event. \textit{Cell Mol Life Sci.} 2016;73:667–683.
18. Hooper NM. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. \textit{Biochem Soc Trans.} 2005;33:335–348.
19. Almeheen HC, Prox J, Puig B, et al. Lack of a disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. \textit{Mol Neurodegener.} 2011:3:6.
20. Stahl N, Baldwin MA, Buttingame AL, Prusiner SB. Identification of glycino-sitol phospholipid linked and truncated forms of the scrapie prion protein. \textit{Biochemistry.} 1990;29:8879–8884.
21. Taylor DR, Parkin ET, Cocklin SL, et al. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. \textit{J Biol Chem.} 2009;284:22590–22600.
22. Tucher J, Linke D, Koudelka T, et al. LC-MS based cleavage site profiling of the prion protein precursor protein and prion protein. \textit{Proteome Res.} 2014;13:2205–2214.
23. Tagliavini F, Prelli F, Porro M, Salmona M, Bugiani O, Frangione B. A soluble form of prion protein in human cerebrospinal fluid: implications for prion-related neurodegenerative diseases. \textit{J Neurosci.} 2005;25:193–200.
24. Wong BS, Green AJ, Li R, et al. Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease. \textit{J Pathol.} 2001;194:9–14.
25. Meyne F, Glocckner SF, Ciesielczyk B, et al. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. \textit{J Alzheimer's Dis.} 2009;17:863–873.
26. Torres M, Cartier L, Matamala JM, Hernandez N, Woehlbier U, Hetz C. Altered prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease. \textit{PLoS ONE.} 2012;7:e36159.
27. Luken A, Cerniles V, Vranac T, Popovic M, Curin-Serbec V. Regional distribution of anchored prion protein, PrP\textsubscript{226}\textsuperscript{*}, in the human brain. \textit{Prion.} 2014;8:203–209.
28. Notari S, Strammiello R, Capellari S, et al. Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease. \textit{J Biol Chem.} 2008;283:30557–30565.
29. Dvorakova E, Vranac T, Janusovska O, et al. Detection of the GPI-anchored prion protein fragment PrP\textsubscript{226}\textsuperscript{*} in human brain. \textit{BMC Neurol.} 2013;13:126.
30. Jansen C, Parchi P, Capellari S, et al. Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. \textit{Acta Neuropathol.} 2010;119:189–197.
31. Parchi P, Chen SG, Brown P, et al. Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease. \textit{Proc Natl Acad Sci U S A.} 1998;95:8322–8327.
32. Tagliavini F, Prelli F, Ghiso J, et al. Amyloid protein of Gerstmann-Sträussler- Scheinker disease (Indiana Kindred) is an 11 kd fragment of prion protein with an N-terminal glycine at codon 58. *EMBO J*. 1991;10:513–519.

33. Chesebro B, Trifilo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. *Science*. 2005;308:1435–1439.

34. Race B, Meade-White K, Oldstone MB, Race R, Chesebro B. Detection of prion infectivity in fat tissues of scrapie-infected mice. *PLoS Pathog*. 2008;4:e1000232.

35. Bett C, Kurt TD, Lucero M, et al. Defining the conformational features of anchorless, poorly neuroinvasive prions. *PLoS Pathog*. 2013;9:e1003280.

36. Chesebro B, Race B, Meade-White K, et al. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. *PLoS Pathog*. 2010;6:e1000880.

37. Rangel A, Race B, Klingeborn M, Striebel J, Chesebro B. Unusual cerebral vascular prion protein amyloid distribution in scrapie-infected transgenic mice expressing anchorless prion protein. *Acta Neuropathol Commun*. 2013;2:15.

38. Rangel A, Race B, Phillips K, Striebel J, Kurz T, Chesebro B. Distinct patterns of spread of prion infection in brains of mice expressing anchorless or anchored forms of prion protein. *Acta Neuropathol Commun*. 2014;2:8.

39. Stohr J, Watts JC, Legname G, et al. Spontaneous generation of anchorless prions in transgenic mice. *Proc Natl Acad Sci U S A*. 2011;108:21223–21228.

40. Race B, Phillips K, Meade-White K, Striebel J, Chesebro B. Increased infectivity of anchorless mouse scrapie prions in transgenic mice overexpressing human prion protein. *J Virol*. 2015;89:6022–6032.

41. Brocker CN, Vasiliou V, Nebert DW. Evolutionary divergence and functions of the ADAM and ADAMTS gene families. *Mol Aspects Med*. 2008;29:258–289.

42. Linsenmeier L, Altmeppen HC, Wetzel S, Mohammadi B, Saftig P, Glatzel M. The ADAM metalloproteinases. *EMBO J*. 2013;10:513–519.

43. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. *J Mol Biol*. 2013;127:415–425.

44. Linsenmeier L, Altmeppen HC, Wetzel S, Mohammadi B, Saftig P, Glatzel M. The ADAM metalloproteinases. *J Mol Biol*. 2013;127:415–425.

45. Brocker CN, Vasiliou V, Nebert DW. Evolutionary divergence and functions of the ADAM and ADAMTS gene families. *Mol Aspects Med*. 2008;29:258–289.

46. Beland M, Bedard M, Tremblay G, Lavigne P, Roucou X. A C-terminal-deleted prion protein fragment is a major accumulated component of systemic PrP deposits in hereditary prion disease with a 2-Bp (CT) deletion in PRNP codon 178. *J Neuropath Exp Neurol*. 2016;75:1008–1019.

47. Seneci P. Molecular Targets in Protein Misfolding and Neurodegenerative Disease. Amsterdam, The Netherlands: Elsevier Science; 2014.

48. Čurin Šerbec V, Bresjanac M, Popović M, et al. Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue. *J Biol Chem*. 2004;279:3694–3698.

49. Kovač V, Zupančič B, Ilc G, Giachin G, et al. Epitope mapping of a PrPSc-specific monoclonal antibody: identification of a novel C-terminally truncated prion protein fragment. *Mol Immunol*. 2011;48:746–750.

50. Kovač V, Zupančič B, Ilc G, Gomide J, Čurin Šerbec V. Truncated prion protein PrP226*: a structural view on its role in amyloid disease. *Biochem Biophys Res Commun*. 2017;484:45–50.

51. Igel G, Giachin G, Jaremko M, et al. Molecular targets of the human prion protein with the pathological Q212P mutation reveals unique structural features. *PLoS ONE*. 2010;5:e11715.

52. Čurin Šerbec V, Hafner-Bratkovič I, Čurin Šerbec V. Anchorless forms of prion protein—impact of truncation on structure destabilization and prion protein conversion. *Biochem Biophys Res Commun*. 2016;468:1–6.